New LaunchJun 4, 2026, 08:01 AM
Dare Bioscience to Launch Flora Sync LF5; First Product Revenue Expected
AI Summary
Dare Bioscience announced the upcoming commercial launch of Flora Sync LF5, a vaginal probiotic capsule, marking its transition to a revenue-generating company with first direct consumer product revenue expected in June 2026. The product will be marketed under the DARE to RESTORE brand and manufactured by Probiotical S.p.A. The company also provided updates on its pipeline, including the initiation of a Phase 2 study for DARE-HPV, positive interim results for Ovaprene, and the targeted summer launch of DARE to PLAY Sildenafil Cream.
Key Highlights
- Dare Bioscience expects first direct consumer product revenue in June 2026 with Flora Sync LF5
- Flora Sync LF5, a vaginal probiotic capsule, will be marketed under DARE to RESTORE
- Flora Sync LF5 will be available without prescription for $49 per box (6 capsules)
- A limited-time launch offer includes 30% off plus free shipping for early registrants
- Initiated Phase 2 clinical study of DARE-HPV, with topline data expected in 2027
- Reported positive interim safety and efficacy results from Phase 3 Ovaprene
- DARE to PLAY Sildenafil Cream dispensing targeted to commence this summer
Price Impact
More from DARE